Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
复制标题
DOI：
10.1146/annurev.med.080608.100623
复制
发表时间：
2010
影响因子：
10.5
通讯作者：
Llovet JM
中科院分区：
文献类型：
--
作者：
Villanueva A;Minguez B;Forner A;Reig M;Llovet JM
基因组时代正在改变对癌症的理解，尽管将大量可用数据转化为决策算法还远未实现。肝细胞癌（HCC）是西方国家中肝细胞癌患者的第一死亡原因和快速增长的恶性肿瘤，其分子谱分析使得能够提出疾病诊断和管理的新方法。大多数HCC发生在肝硬化的肝脏上，并且可以预见的是，准确的基因组表征将允许鉴定适合于化学预防策略中的选择性靶点的促癌信号。分子诊断目前对小肿瘤是可行的，但尚未被科学指南采用。索拉非尼在晚期患者中获得前所未有的生存益处后，分子治疗成为现实。来自肿瘤和非肿瘤组织的基因组信息将有助于预后预测，并有助于识别癌基因成瘾环，为更个性化的药物提供机会。
The genomic era is changing the understanding of cancer, although translation of the vast amount of data available into decision-making algorithms is far from reality. Molecular profiling of hepatocellular carcinoma (HCC), the first cause of death among cirrhotic patients and a fast growing malignancy in Western countries, is enabling to propose novel approaches to disease diagnosis and management. Most HCC arise on a cirrhotic liver, and predictably, an accurate genomic characterization will allow the identification of pro-carcinogenic signals amenable for selective target within chemopreventive strategies. Molecular diagnosis is currently feasible for small tumors, but it has not yet been adopted by scientific guidelines. Molecular treatment is a reality after the unprecedented survival benefits obtained by sorafenib in patients at advanced stages. Genomic information from tumor and non-tumoral tissue will aid prognosis prediction, and facilitate the identification of oncogene addiction loops, providing the opportunity to a more personalized medicine.
登录
查看更多内容
影响因子：
56.9
作者：
Golub, TR;Slonim, DK;Lander, ES
通讯作者：
Lander, ES
影响因子：
51.1
作者：
Faivre, Sandrine;Raymond, Eric;Cheng, Ann Lii
通讯作者：
Cheng, Ann Lii
影响因子：
25.7
作者：
Di Tommaso, Luca;Destro, Annarita;Roncalli, Massimo
通讯作者：
Roncalli, Massimo
影响因子：
158.5
作者：
Kobayashi, S;Boggon, TJ;Halmos, B
通讯作者：
Halmos, B
DOI：
10.1056/nejmoa0804525
发表时间：
2008-11-06
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hoshida Y;Villanueva A;Kobayashi M;Peix J;Chiang DY;Camargo A;Gupta S;Moore J;Wrobel MJ;Lerner J;Reich M;Chan JA;Glickman JN;Ikeda K;Hashimoto M;Watanabe G;Daidone MG;Roayaie S;Schwartz M;Thung S;Salvesen HB;Gabriel S;Mazzaferro V;Bruix J;Friedman SL;Kumada H;Llovet JM;Golub TR
通讯作者：
Golub TR